194 related articles for article (PubMed ID: 24348046)
1. Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.
Gadiot J; Hooijkaas AI; Deken MA; Blank CU
Onco Targets Ther; 2013; 6():1649-58. PubMed ID: 24348046
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
3. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
[TBL] [Abstract][Full Text] [Related]
5. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
6. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
Dinter L; Karitzky PC; Schulz A; Wurm AA; Mehnert MC; Sergon M; Tunger A; Lesche M; Wehner R; Müller A; Käubler T; Niessner H; Dahl A; Beissert S; Schmitz M; Meier F; Seliger B; Westphal D
Int J Cancer; 2024 Mar; 154(6):1057-1072. PubMed ID: 38078628
[TBL] [Abstract][Full Text] [Related]
7. Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation.
Meirson T; Asher N; Bomze D; Markel G
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32580351
[No Abstract] [Full Text] [Related]
8. Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study.
Salzmann M; Wald A; Stege H; Loquai C; Zimmer L; Hayani KM; Heinzerling L; Gutzmer R; Enk AH; Hassel JC
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900217
[TBL] [Abstract][Full Text] [Related]
9. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.
Tiago M; Capparelli C; Erkes DA; Purwin TJ; Heilman SA; Berger AC; Davies MA; Aplin AE
Br J Cancer; 2020 Mar; 122(6):789-800. PubMed ID: 31932756
[TBL] [Abstract][Full Text] [Related]
10. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
Bonfill-Teixidor E; Iurlaro R; Handl C; Wichmann J; Arias A; Cuartas I; Emmenegger J; Romagnani A; Mangano L; Lorber T; Berrera M; Godfried Sie C; Köchl F; Eckmann J; Feddersen R; Kornacker M; Schnetzler G; Cicuendez M; Cordero E; Topczewski TE; Ferres-Pijoan A; González J; Martínez-Ricarte F; Muñoz-Couselo E; Tabernero J; Bischoff JR; Pettazzoni P; Seoane J
Cancer Res; 2022 Jul; 82(14):2552-2564. PubMed ID: 35584009
[TBL] [Abstract][Full Text] [Related]
11. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
Mettler C; Monnet D; Kramkimel N; Tréluyer JM; Mouthon L; Brézin A; Dupin N; Valnet-Rabier MB; Chouchana L; Terrier B
Ophthalmology; 2021 Dec; 128(12):1748-1755. PubMed ID: 34000304
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study.
Liu X; Li JJ; Ding Y; Li DD; Wen XZ; Weng DS; Wang JH; Jiang H; Zhang XS
Front Oncol; 2021; 11():582676. PubMed ID: 33868987
[TBL] [Abstract][Full Text] [Related]
13. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma.
Cybulska-Stopa B; Rogala P; Czarnecka AM; Galus Ł; Dziura R; Rajczykowski M; Kubiatowski T; Wiśniewska M; Gęga-Czarnota A; Teterycz P; Ziobro M; Suwiński R; Mackiewicz J; Rutkowski P
Melanoma Res; 2020 Oct; 30(5):465-471. PubMed ID: 32221131
[TBL] [Abstract][Full Text] [Related]
14. Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive
Rossi E; Schinzari G; Cellini F; Balducci M; Pasqualoni M; Maiorano BA; Fionda B; Longo S; Deodato F; Di Stefani A; Peris K; Gambacorta MA; Tortora G
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830931
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Long GV; Arance A; Mortier L; Lorigan P; Blank C; Mohr P; Schachter J; Grob JJ; Lotem M; Middleton MR; Neyns B; Steven N; Ribas A; Walpole E; Carlino MS; Lebbe C; Sznol M; Jensen E; Leiby MA; Ibrahim N; Robert C
Ann Oncol; 2022 Feb; 33(2):204-215. PubMed ID: 34710571
[TBL] [Abstract][Full Text] [Related]
16. Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study.
Huynh S; Mortier L; Dutriaux C; Maubec E; Boileau M; Dereure O; Leccia MT; Arnault JP; Brunet-Possenti F; Aubin F; Dreno B; Beylot-Barry M; Lebbe C; Lefevre W; Delyon J
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32585901
[TBL] [Abstract][Full Text] [Related]
17. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
18. Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas.
Acciardo S; Mignion L; Joudiou N; Bouzin C; Baurain JF; Gallez B; Jordan BF
Oncotarget; 2018 Mar; 9(24):16832-16846. PubMed ID: 29682188
[TBL] [Abstract][Full Text] [Related]
19. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
20. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
